264 results on '"Qiu, Shaowei"'
Search Results
2. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells
3. Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia
4. Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
5. Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia
6. A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects
7. Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy
8. The RTK–RAS signaling pathway is enriched in patients with rare acute myeloid leukemia harboring t(16;21)(p11;q22)/FUS: ERG
9. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling
10. 2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway
11. Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells
12. Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition
13. Slow‐replicating leukemia cells represent a leukemia stem cell population with high cell‐surface CD74 expression.
14. Tracking The Molecular Dynamics of Lineage Switch Under CD19 CAR-T Treatment in Non-KMT2A Rearranged B-ALL Patients
15. Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
16. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1–RUNX1T1
17. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells
18. Pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China
19. Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
20. Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature review
21. RTK-RAS Signaling Pathway Was Enriched in Rare Acute Myeloid Leukemia Patients with t(16;21)(p11;q22)/ FUS::ERG
22. Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells
23. Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline‐Induced Cardiomyopathy – A COG‐ALTE03N1 Report
24. SIRT1 regulates metabolism and leukemogenic potential in CML stem cells
25. High-doses Granulocyte Colony-stimulating Factor (G-CSF) Benefit Elderly Patients with Acute Myeloid Leukemia
26. Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
27. Figure S4 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
28. Supplementary Tables S1-S5 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
29. A novel subclonal rearrangement of the STRN3::PDGFRB genes in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects
30. Low c-Kit expression identifies primitive, therapy-resistant CML stem cells
31. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling
32. The Anti-Leprosy Agent Clofazimine Inhibits FLT3-ITD Mutant AML Stem Cells and Potently Enhances Effects of TKI
33. Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)
34. PRMT5 Inhibition Enhances Elimination of FLT3-ITD AML Stem Cells in Combination with TKI Treatment
35. Investigation of Impact Induced By AML1-ETO on Self-Renewal and Differentiation of Hematopoietic Stem and Progenitor Cells in Pre-Leukemic Stage
36. Construction of Dual- and Enhanced Dual-Antibodies Targeting CD19 in the Treatment of B-ALL and Investigation of the Relevant Mechanisms
37. The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma
38. Targeting Interferon Pathway in TBLR1-RARa-Driven Promyelocytic Leukemia in the Context of ATRA and ATO Unresponsiveness
39. Metabolic Adaptation to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukemia Stem Cells
40. Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells
41. The Characteristics of AML1-ETO Fusion Gene Induced Pre-Leukemia Immune Microenvironment
42. N-Cadherin and Tie2 positive CD34+CD38−CD123+ leukemic stem cell populations can develop acute myeloid leukemia more effectively in NOD/SCID mice
43. Flow cytometric analysis of cerebrospinal fluid in adult patients with acute lymphoblastic leukemia during follow‐up
44. Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population
45. Clinical and laboratory studies of 17 patients with acute myeloid leukemia harboring t(7;11)(p15;p15) translocation
46. The prognostic factors in acute myeloid leukaemia with double‐mutated CCAAT/enhancer‐binding protein alpha( CEBPA dm)
47. Clinical, Cytogenetic Characteristics and Survival of Acute Leukemia in a National Research Center Database, 10-Year Real-World Data Review
48. Essential Roles of Transcription Factor MEF2D in the Maintenance of MLL-Rearranged Acute Myeloid Leukemia
49. Evaluation of pretreatment telomere length as a prognostic marker in intermediate‐risk acute myeloid leukemia
50. Additional file 1 of Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.